Home/Pipeline/Tadliq® (Tadalafil Oral Suspension)

Tadliq® (Tadalafil Oral Suspension)

Pulmonary Arterial Hypertension

ApprovedMarketed

Key Facts

Indication
Pulmonary Arterial Hypertension
Phase
Approved
Status
Marketed
Company

About CMP Pharma

Founded in 1975, CMP Pharma is a legacy pharmaceutical company dedicated to creating customized oral liquid and topical formulations for patients underserved by traditional solid dosage forms, particularly in acute and long-term care settings. The company has achieved significant milestones with FDA approvals for novel liquid formulations of established drugs, including Norliqva (amlodipine), Tadliq (tadalafil), and CaroSpir (spironolactone). CMP's strategy centers on identifying niche therapeutic markets, developing high-value alternative dosage forms, and manufacturing products at its facility in Farmville, North Carolina, for distribution to hospitals, long-term care facilities, and retail channels.

View full company profile

Other Pulmonary Arterial Hypertension Drugs

DrugCompanyPhase
GSK3640254GSK plcPhase 2
PAH ProgramInsmedPhase 2b
Treprostinil (Remodulin)United TherapeuticsCommercial
Treprostinil (Orenitram)United TherapeuticsCommercial
Selexipag (Uptravi)United TherapeuticsCommercial
RalinepagUnited TherapeuticsPhase 3
Orenitram®Supernus PharmaceuticalsApproved/Commercial